{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:58:48Z","timestamp":1790391528871,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Innovationsfond, Germany","award":["01VSF25057"],"award-info":[{"award-number":["01VSF25057"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognostic impact of the diagnosis-to-treatment interval (DTI) in diffuse large B-cell lymphoma (DLBCL) remains controversial. We investigated the association between DTI and three-year all-cause mortality in a nationwide cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective population-based cohort study using harmonised German cancer registry data (2020\u20132023), with vital status follow-up until December 2024. Patients with a first primary DLBCL diagnosis were included. Kaplan\u2013Meier analyses and Cox regression assessed DTI in relation to survival, unadjusted and adjusted for patient, tumor, and structural characteristics. Missing International Prognostic Index (IPI) data formed a separate category, with complete-case and imputation sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 16,443 patients, 10,872 initiated systemic therapy within 56\u00a0days (eight weeks) and entered the primary analysis. Median age was 71\u00a0years, 44.2% were female, and median follow-up was 1.5\u00a0years. Three-year overall survival ranged from\u2009~\u200963% to 75% across the five treatment-week groups. Compared with week 1, later initiation was associated with progressively lower hazard of death (week 3: HR 0.72, 95% CI 0.64\u20130.81; week 4: HR 0.63, 0.55\u20130.72; weeks 5\u20138: HR 0.62, 0.54\u20130.70). Lower-risk IPI predicted better survival (low risk: HR 0.24, 0.17\u20130.34 vs high risk). Later initiation was predicted by low-risk IPI (+\u20097.89\u00a0days), older age (+\u20090.62\u00a0days\/SD), and surviving the first year (+\u20093.26\u00a0days).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early treatment in DLBCL is primarily driven by adverse disease characteristics. A residual association between longer DTI and improved survival persisted after IPI adjustment, suggesting DTI may be an independent prognostic factor in less aggressive disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-17024-9","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:43:45Z","timestamp":1790387025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights into the survival impact of delayed immunochemotherapy in newly diagnosed diffuse large B-cell lymphoma: results from a nationwide registry study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-3155","authenticated-orcid":false,"given":"Susanne","family":"von Kroge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Janis","family":"Steinhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Walk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Kusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"LYSED study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf v.d.","family":"Knesebeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareile","family":"Beernink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gundler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"\u00dcckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobst","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Semmelhaack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Sassenberg-Gummert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"issue":"4","key":"17024_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMOA2115304\/SUPPL_FILE\/NEJMOA2115304_DATA-SHARING.PDF","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351\u201363. https:\/\/doi.org\/10.1056\/NEJMOA2115304\/SUPPL_FILE\/NEJMOA2115304_DATA-SHARING.PDF. PubMed PMID: 34904799.","journal-title":"N Engl J Med"},{"issue":"9","key":"17024_CR2","doi-asserted-by":"publisher","first-page":"e70207","DOI":"10.1002\/HEM3.70207","volume":"9","author":"C Thieblemont","year":"2025","unstructured":"Thieblemont C, Gomes Da Silva M, Lepp\u00e4 S, Lenz G, Cottereau AS, Fox C, et al. Large B\u2010cell lymphoma (LBCL): EHA clinical practice guidelines for diagnosis, treatment, and follow\u2010up. Hemasphere. 2025;9(9):e70207. https:\/\/doi.org\/10.1002\/HEM3.70207. PubMed PMID: 40995463.","journal-title":"Hemasphere"},{"issue":"Suppl 1","key":"17024_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/BJC.2015.48","volume":"112","author":"RD Neal","year":"2015","unstructured":"Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112(Suppl 1):92\u2013107. https:\/\/doi.org\/10.1038\/BJC.2015.48. PubMed PMID: 25734382.","journal-title":"Br J Cancer"},{"issue":"1","key":"17024_CR4","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/J.CLML.2024.09.012","volume":"25","author":"J Allen","year":"2025","unstructured":"Allen J, Abbott D, Eskandar J, Bair SM, Haverkos B, Jasem J, et al. DA-R-EPOCH may mitigate the adverse prognostic implication of the diagnosis-to-treatment interval (DTI) in large B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2025;25(1):e26-33. https:\/\/doi.org\/10.1016\/J.CLML.2024.09.012. PubMed PMID: 39426945.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"17024_CR5","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1182\/BLOOD-2018-99-120313","volume":"132","author":"DN Blunt","year":"2018","unstructured":"Blunt DN, Smyth L, Gatov E, Nagamuthu C, Buckstein R, Croxford R, et al. Diagnosis to treatment interval in DLBCL is predictive of overall survival in a large, population-based registry. Blood. 2018;132(Supplement 1):1700. https:\/\/doi.org\/10.1182\/BLOOD-2018-99-120313.","journal-title":"Blood"},{"issue":"3","key":"17024_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/10428194.2018.1508671","volume":"60","author":"V Camus","year":"2019","unstructured":"Camus V, Dubois S, Jardin F, Tilly H. Prognostic impact of diagnosis to treatment interval (DTI) in diffuse large B-cell lymphoma patients: a real-life monocentric study. Leuk Lymphoma. 2019;60(3):839\u201341. https:\/\/doi.org\/10.1080\/10428194.2018.1508671. PubMed PMID: 30234405.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"17024_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/BJH.15224","volume":"181","author":"AJ Olszewski","year":"2018","unstructured":"Olszewski AJ, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol. 2018;181(4):495\u2013504. https:\/\/doi.org\/10.1111\/BJH.15224. PubMed PMID: 29687879.","journal-title":"Br J Haematol"},{"issue":"2","key":"17024_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/BJH.16078","volume":"187","author":"S Lee","year":"2019","unstructured":"Lee S, Fujita K, Negoro E, Morishita T, Yamauchi H, Oiwa K, et al. The impact of diagnostic wait time on the survival of patients with diffuse large B-cell lymphoma: effect modification by the International Prognostic Index. Br J Haematol. 2019;187(2):195\u2013205. https:\/\/doi.org\/10.1111\/BJH.16078. PubMed PMID: 31247676.","journal-title":"Br J Haematol"},{"issue":"1","key":"17024_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-82615-4","volume":"11","author":"M Yoshida","year":"2021","unstructured":"Yoshida M, Nakaya Y, Shimizu K, Tatsumi N, Tsutsumi M, Fuseya H, et al. Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma. Sci Rep. 2021;11(1):1\u20137. https:\/\/doi.org\/10.1038\/s41598-021-82615-4. PubMed PMID: 33531642.","journal-title":"Sci Rep"},{"issue":"3","key":"17024_CR10","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/J.CLML.2023.11.003","volume":"24","author":"G Roman Souza","year":"2024","unstructured":"Roman Souza G, Nooruddin Z, Lee S, Boyle L, Lucero KT, Ananth S, et al. The impact of time from diagnosis to initiation of chemotherapy on survival of patients with newly diagnosed diffuse large B-cell lymphoma in the Veterans Health Administration. Clin Lymphoma Myeloma Leuk. 2024;24(3):e67-77. https:\/\/doi.org\/10.1016\/J.CLML.2023.11.003. PubMed PMID: 38151390.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"17024_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/10428194.2015.1055480","volume":"57","author":"K Hay","year":"2016","unstructured":"Hay K, Lee B, Goktepe O, Connors JM, Sehn LH, Savage KJ, et al. Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(2):276\u201382. https:\/\/doi.org\/10.3109\/10428194.2015.1055480. PubMed PMID: 26010123.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"17024_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/BJH.13150","volume":"168","author":"A Nikonova","year":"2015","unstructured":"Nikonova A, Guirguis HR, Buckstein R, Cheung MC. Predictors of delay in diagnosis and treatment in diffuse large B-cell lymphoma and impact on survival. Br J Haematol. 2015;168(4):492\u2013500. https:\/\/doi.org\/10.1111\/BJH.13150. PubMed PMID: 25324181.","journal-title":"Br J Haematol"},{"issue":"16","key":"17024_CR13","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2017.76.5198","volume":"36","author":"MJ Maurer","year":"2018","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Link BK, Jais JP, Habermann TM, Thompson CA, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol. 2018;36(16):1603\u201310. https:\/\/doi.org\/10.1200\/JCO.2017.76.5198. PubMed PMID: 29672223.","journal-title":"J Clin Oncol"},{"key":"17024_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15153934","author":"A Katalinic","year":"2023","unstructured":"Katalinic A, Halber M, Meyer M, Pfl\u00fcger M, Eberle A, Nennecke A, et al. Population-based clinical cancer registration in Germany. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/CANCERS15153934. PubMed PMID: 37568750.","journal-title":"Cancers (Basel)"},{"key":"17024_CR15","doi-asserted-by":"publisher","unstructured":"Ghandili S, Dierlamm J, Bokemeyer C, Kusche H, Peters F. A German perspective on the impact of socioeconomic status in diffuse large B-cell lymphoma. Blood Cancer J. 2024;14(1). https:\/\/doi.org\/10.1038\/S41408-024-01158-9. PubMed PMID: 39394192.","DOI":"10.1038\/S41408-024-01158-9"},{"key":"17024_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/HEM3.70011","author":"S Ghandili","year":"2024","unstructured":"Ghandili S, Dierlamm J, Bokemeyer C, Kusche H, Peters F. The changing influence of neighborhood socioeconomic status on long-term survival in diffuse large B-cell lymphoma patients: a German metropolitan case-control study spanning over three decades. Hemasphere. 2024. https:\/\/doi.org\/10.1002\/HEM3.70011. PubMed PMID: 39380842.","journal-title":"Hemasphere"},{"issue":"6","key":"17024_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/S00761-025-01721-4","volume":"31","author":"A Schultz","year":"2025","unstructured":"Schultz A, Ghandili S, Kim-Wanner SZ, Neuser P, Peters F. Fact sheet: epidemiology of non-Hodgkin lymphoma in Germany from 2013 to 2022. Onkologie. 2025;31(6):525\u201334. https:\/\/doi.org\/10.1007\/S00761-025-01721-4.","journal-title":"Onkologie"},{"key":"17024_CR18","unstructured":"INKAR - BBSR. Available from: https:\/\/www.inkar.de\/. Cited 2025 Oct 11."},{"issue":"Suppl 5","key":"17024_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.25646\/10641","volume":"7","author":"N Michalski","year":"2022","unstructured":"Michalski N, Reis M, Tetzlaff F, Herber M, Kroll LE, H\u00f6vener C, et al. German Index of Socioeconomic Deprivation (GISD): revision, update and applications. J Health Monit. 2022;7(Suppl 5):2. https:\/\/doi.org\/10.25646\/10641. PubMed PMID: 36628258.","journal-title":"J Health Monit"},{"key":"17024_CR20","unstructured":"OncoMap - Liste der zertifizierten Krebszentren. Available from: http:\/\/www.oncomap.de\/centers?showMap=1. Cited 2025 Sep 7."},{"issue":"6","key":"17024_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.6004\/JNCCN.2020.7654","volume":"19","author":"DN Blunt","year":"2021","unstructured":"Blunt DN, Smyth L, Nagamuthu C, Gatov E, Croxford R, Mozessohn L, et al. Shorter diagnosis-to-treatment interval in diffuse large B-cell lymphoma is associated with inferior overall survival in a large, population-based registry. J Natl Compr Canc Netw. 2021;19(6):719\u201325. https:\/\/doi.org\/10.6004\/JNCCN.2020.7654. PubMed PMID: 33691276.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"17024_CR22","doi-asserted-by":"publisher","first-page":"e71920","DOI":"10.1002\/CAM4.71920","volume":"15","author":"K Joonas","year":"2026","unstructured":"Joonas K, Katja M, Susanna T, Marjukka P, Sirkku J, Minna S, et al. Socioeconomic status and access to treatment in diffuse large B-cell lymphoma. Cancer Med. 2026;15(5):e71920. https:\/\/doi.org\/10.1002\/CAM4.71920. PubMed PMID: 42108510.","journal-title":"Cancer Med"},{"issue":"9","key":"17024_CR23","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/BLOODADVANCES.2021004665","volume":"5","author":"EJ Bataillard","year":"2021","unstructured":"Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, El-Galaly TC. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Adv. 2021;5(9):2426. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2021004665. PubMed PMID: 33961018.","journal-title":"Blood Adv"},{"key":"17024_CR24","unstructured":"LYSED \u2013 Analyse von Zusammenh\u00e4ngen zwischen sozio\u00f6konomischer Benachteiligung, Komorbidit\u00e4ten und deren Auswirkung auf Lymphom-Patient:innen - G-BA Innovationsfonds. Available from: https:\/\/innovationsfonds.g-ba.de\/projekte\/lysed.788. Cited 2026 May 17."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-17024-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-17024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-17024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:59:49Z","timestamp":1790387989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-17024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["17024"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-17024-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"29 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For this analysis, ethics committee review and informed consent are not required according to federal law. According to Section 6, Paragraph 2 of the HmbKrebsRG, the Hamburg Cancer Registry may participate in scientific studies on cancer if no individual can be identified. Moreover, the Hamburg Cancer Registry has permission to use data from other state cancer registries for this purpose. We confirm that all analyses were performed in accordance with relevant guidelines (Declaration of Helsinki) and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1144"}}